




Product Introduction

Irinotecan HCl Trihydrate

Irinotecan prevents DNA from unwinding by inhibition of **topoisomerase 1**.

Technical Data:

Molecular Weight (MW):	677.18	
Formula:	C ₃₃ H ₃₈ N ₄ O ₆ .HCl.3H ₂ O	
Solubility (25°C)	DMSO 100 mg/mL	
* <1 mg/ml means slightly soluble or insoluble:	Water 1 mg/mL	
	Ethanol 7 mg/mL	
Purity:	>98%	
Storage:	3 years -20°C Powder 6 months-80°C in DMSO	
CAS No.:	136572-09-3	

Biological Activity

Irinotecan (20 mg/kg i.p.) induces tumor growth inhibition of 92% in COLO 320 xenograft mice model. ^[3] Irinotecan (100 mg/kg) significantly increases amounts of topoisomerase I covalently bound to DNA in stomach, duodenum, colon and liver in male Wistar rats. ^[4] Irinotecan (200 mg/kg) induces severe diarrhea and lethality in treated rats. ^[5]

Irinotecan (20 mg/kg i.p.) induces a maximum growth inhibition of 92% on day 42 in COLO 320 xenograft mice model. ^[3] Irinotecan (100 mg/kg) significantly increases amounts of topoisomerase I covalently bound to DNA in stomach, duodenum, colon and liver in male Wistar rats. ^[4] Irinotecan (200 mg/kg)

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

induces a 93-100% incidence of severe diarrhea and an 86-100% incidence of lethality in treated rats, while IL-15 (100 mg/kg or 400 mg/kg) protects against CPT-11-induced toxicity. CPT-11 (200 mg/kg) alone produces serious damage to duodenal villi and colonic crypts in rats. ^[5]

Irinotecan is a prodrug which needs to be transformed by carboxylesterases to its active metabolite SN-38.

References

[1] Pavillard V, et al. *Cancer Chemother Pharmacol*, 2002, 49(4), 329-335.

[2] Magrini R, et al. *Int J Cancer*, 2002, 101(1), 23-31.

[3] Jansen WJ, et al. *Int J Cancer*, 1997, 70(3), 335-340.

[4] Barth SW, et al. *Biotechnol J*, 2010, 5(3), 321-327.

[5] Cao S, et al. *Cancer Res*, 1998, 58(15), 3270-3274.



Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.